Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI

被引：2
|
作者：
Riess, J. [1 ]
Kelly, K. [1 ]
Schalper, K. [2 ]
Shimoda, M. [3 ]
Lim, S. [1 ]
Monjazeb, A. [1 ]
Danenberg, K. [4 ]
Moore, E. [1 ]
Beckett, L. [1 ]
Mack, P. [1 ]
Maverakis, E. [3 ]
Gandara, D. [1 ]
机构：
[1] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
[2] Yale Univ, Pathol, New Haven, CT USA
[3] Univ Calif Davis, Sch Med, Dermatol, Sacramento, CA USA
[4] Nanthealth, Liquid Genom, Torrance, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
immune microenvironment; EGFR-mutant NSCLC; Immunotherapy;
D O I：
10.1016/j.jtho.2018.08.724
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-09
引用
收藏
页码：S528 / S528
页数：1
相关论文
共 50 条
  • [21] TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
    Han, J-Y.
    Sequist, L. V.
    Ahn, M-J.
    Cho, B. C.
    Yu, H.
    Kim, S-W.
    Yang, J. C-H.
    Lee, J. S.
    Su, W-C.
    Kowalski, D.
    Orlov, S.
    Cantarini, M.
    Verheijen, R. B.
    Mellemgaard, A.
    Frewer, P.
    Ou, X.
    Oxnard, G.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [22] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
    Niina Laurila
    Jussi P. Koivunen
    [J]. Medical Oncology, 2015, 32
  • [23] CYTOPLASMIC ERBEXPRESSION PREDICTS POORLY EFFICACY AND SURVIVAL OF EGFR-TKI IN EGFR MUTANT NSCLC
    Wang, Zhijie
    Li, Zhenxiang
    Bai, Hua
    Wang, Jie
    Zhao, Jun
    Wu, Meina
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S354 - S354
  • [24] Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
    Qian, Xiaoyu
    Guo, Xiaodan
    Li, Ting
    Hu, Wei
    Zhang, Lin
    Wu, Caisheng
    Ye, Feng
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [25] Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
    Chang, John Wen-Cheng
    Huang, Chen-Yang
    Fang, Yueh-Fu
    Chang, Ching-Fu
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Hsu, Ping-Chih
    Wu, Chiao-En
    [J]. CANCERS, 2022, 14 (04)
  • [26] EGFR-mutant NSCLC cells upregulate the expression of inhibitory immune checkpoint CD24 under EGFR-TKI treatment
    Shiiya, Akihiko
    Noguchi, Takuro
    Ariga, Shin
    Ohhara, Yoshihito
    Shimizu, Yasushi
    Kinoshita, Ichiro
    Akita, Hirotoshi
    [J]. CANCER SCIENCE, 2023, 114 : 427 - 427
  • [27] The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
    Huang, Y. H.
    Hsu, K. -H.
    Tseng, J. -S.
    Chen, K. -C.
    Chang, G. -C.
    Yang, T. -Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S477 - S478
  • [28] Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC
    Zhu, Y.
    Chen, Y.
    Han, S.
    Ying, X.
    Sun, X.
    Xu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S502 - S502
  • [29] Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Tsai, Chi-Ren
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Tsai, Meen-Hsin
    Yu, Sung-Liang
    Su, Kang-Yi
    Chen, Jeremy J. W.
    Chang, Gee-Chen
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (04) : 603 - 610
  • [30] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
12345